NEU is materially undervalued, page-11

Maximum value will be achieved once the Phase 3 trials are complete.

Combining information for the Investor Webinar and the numbers provided by Little T above you can see that NEU are in a very strong financial position and can afford to fund two Phase 3 trials.

Jon Pilcher says the cost of running a Phase 3 trail could be between US$50m and US$150m (A$75m to A$225m).

The numbers above from Little T indicate there is sufficient funds:

+ $213m cash on hand (30^th June 2024)

+ $10m interest potential (c.5%) on cash balance

+ $50m (US$33m) 1/3 of Priority Review Voucher

+ $150m (US$100m) full value of Priority Review Voucher for NNZ259

+ Ongoing royalties Daybue royalties

= more than enough cash to run two Phase 3 trials

From a timing perspective it could take 2-3 years (based on Trof P3 + FDA approval) but assuming they are successful would result in a significant increase in value for NEU and all shareholders.

Here's the link to the webinar so people can hear it direct from Jon. It's a worthwhile investment of time for any Investor in NEU:
Neuren Investor Webinar - NNZ-2591 Angelman syndrome Phase 2 trial top-line results